Present state of intestinal transplantation in Japan

Pediatr Surg Int. 2023 Sep 27;39(1):276. doi: 10.1007/s00383-023-05552-5.

Abstract

Introduction: Intestinal transplantation (ITx) is the ultimate treatment for intestinal failure (IF). In Japan, most cases of IF are a result of pediatric disease, including secondary or congenital intestinal disease or allied disorders of Hirschsprung's disease. Here, we report the results of the Japanese ITx registry.

Methods: A web-based survey form was completed. We investigated the number, age, sex, indication, surgical procedure, immunosuppressants, postoperative course, and the effects of transplantation in patients who underwent cadaveric or living-donor ITx.

Results: By the end of 2022, 42 cases of ITx have been performed in 38 patients in Japan. The donor sources included cadavers (29 cases) and living donors (13 cases). The surgical method was isolated ITx (N = 40) and combined liver and ITx (n = 2). Survival rates were 92%, 73%, and 59% at 1 year, 5 years, and 10 years, respectively. Ninety percent of patients completely discontinued parenteral nutrition. Approximately 80% of the patients had a performance status of 1 or less, indicating that the QOL of patients after ITx was extremely good.

Conclusion: The results of ITx are acceptable to treat IF patients and the QOL after transplantation is also good.

Keywords: Everolimus; Intestinal failure; Motility disorder; Parental nutrition; Short bowel syndrome; Small bowel transplantation.

MeSH terms

  • Child
  • Humans
  • Intestinal Diseases* / surgery
  • Intestines
  • Japan
  • Living Donors
  • Quality of Life
  • Retrospective Studies
  • Short Bowel Syndrome* / surgery